F-18 · Reimbursement, Briefly
A new cancer drug clears its final trial, the FDA signs off, and the company issues a press release with the word approved in the headline. A patient who has been waiting for exactly this drug hears the news, asks her oncologist for it, and is told she can’t have it yet. Not because the drug is unsafe. Not because it’s illegal. Because her insurance plan hasn’t agreed to cover it — and even once it does, she’ll need her doctor to file paperwork proving she tried two cheaper drugs first.
This happens constantly, and it blindsides almost everyone the first time they see it. The natural assumption is that “approved” means “available.” It doesn’t. An FDA approval is permission to sell a drug in the United States — a statement that the drug works and is safe enough to be on the market (SP-11). It is not a promise that anyone will pay for it.
That gap — between a drug being legal to sell and a drug actually reaching a patient — is where this primer lives. It is, by a wide margin, the most under-taught part of how medicine actually gets to people. The science can be brilliant and the FDA can be satisfied, and the molecule will still wait at one more door, the one marked covered.
